ARA-190

🧬 ARA-290 (Cibinetide) – Potential Benefits**

🛡️ **Supports Nerve Repair**

⚡ May help promote regeneration of small nerve fibers and support recovery from nerve-related injuries. ([PubMed Central (PMC)][1])

🔥 **Reduces Inflammation**

🌿 Activates the body's innate repair receptor, which may help reduce inflammation without stimulating red blood cell production like erythropoietin (EPO). ([HealthRX.com][2])

😌 **May Reduce Nerve Pain**

💥 Studied for improving symptoms of neuropathic pain, including diabetic and small-fiber neuropathy. ([PubMed][3])

🧠 **Neuroprotective Effects**

🛡️ May help protect nerve cells from damage caused by inflammation or metabolic stress. ([PubMed Central (PMC)][1])

🩹 **Supports Tissue Healing**

🔬 May promote tissue repair by activating the body's natural healing pathways. ([HealthRX.com][2])

🩸 **May Improve Metabolic Health**

📉 Early clinical research has shown improvements in blood sugar markers and lipid profiles in people with type 2 diabetes, though larger studies are needed. ([PubMed Central (PMC)][1])

💪 **Does Not Increase Red Blood Cell Count**

🩸 Unlike erythropoietin (EPO), ARA-290 is designed to provide tissue-protective effects without increasing hematocrit or blood viscosity. ([HealthRX.com][2])

### ⚠️ Possible Side Effects

🤕 Mild headache

💉 Injection-site redness or discomfort

😴 Mild fatigue

🤢 Mild nausea (uncommon)

Clinical trials have generally reported that ARA-290 is well tolerated, but human data remain limited. ([PubMed Central (PMC)][1])

> **Note:** ARA-290 (also known as **Cibinetide**) is an **investigational peptide** and is **not FDA-approved**. While early clinical studies have shown promising results for nerve repair, neuropathic pain, and inflammation, additional large-scale trials are needed to establish its long-term safety and effectiveness.